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for colon cancer
In rectal cancer there is much less scientific evidence for clin-
ically relevant gains from postoperative chemotherapy than
there is for colon cancer. The large adjuvant trials that re-
vealed the gains in disease-free survival (DFS) and overall sur-
vival (OS) included either patients with colon cancer only or a
limited number of patients with rectal cancer. In comparison
with colon cancer, combination chemotherapy with a fluoro-
pyrimidine and oxaliplatin has not been explored at all in rec-
tal cancer, whereas three large randomised trials in colon
cancer all showed improved DFS and possibly OS in patients
randomised to combination therapy [1–3].
Incoloncancer, the loco-regional therapyhasnot changed to
anymajor extent during recent decades. This has been the case
for rectal cancer,where thequality of surgery has beensubstan-
tially improved with the introduction of the total mesorectal
excision (TME) concept. Furthermore, a great majority of rectal
cancerpatientsnowreceivepreoperative therapy, at least if they
belong to the intermediateor locallyadvancedgroups, andpost-
operative radiotherapy or chemoradiotherapy is seldom given
as it oftenwas in recent decades [4–6]. Thismore complex treat-
ment scenario, and the improvements over time of the loco-
regional treatment strategies, have made it difficult to evaluate
the effects of adjuvant chemotherapy in rectal cancer.
Two opposing views can be considered when giving rec-
ommendations for whether or not to give adjuvant chemo-
therapy to rectal cancer patients. One is to extrapolate from
colon cancer, applying the knowledge achieved from the large
trials to rectal cancer under the assumption that they all
come from the same organ and all are adenocarcinomas.
The other view is to look at the trials in detail, explore what
types of loco-regional treatment have been given and then
evaluate whether we have randomised evidence for favour-
able effects in the different clinical situations.2. Do rectal and colon cancers respond
similarly to chemotherapy?
In metastatic disease, the primary location of the colorectal
cancer appears to be irrelevant on the basis of numerous
studies which have analysed the relevance of the tumour site
(colon versus rectum), e.g. Ko¨hne et al [7]. Thus, a possible
reason for the apparently greater effect of adjuvant chemo-
therapy with modulated 5-fluorouracil (5-FU) in colon than
in rectum cancer is probably not due to different chemosensi-
tivities. No study has explored the value of capecitabine or a
combination regimen with a fluoropyrimidine and oxaliplatin
as adjuvant therapy in rectal cancer, whereas these treat-
ments have been extensively used in metastatic disease [8],
with no detectable differences according to site.
Detectable metastases do come from tumour cells/cell
deposits that once have been subclinical and present at the
time of diagnosis. Thus, the lack of difference in the meta-
static setting strongly argues against lower chemosensitivity
of rectal cancer cells compared with colon cancer cells. How-
ever, colon cancer differs in some aspects relevant to tumour
biology, and thus potentially chemosensitivity, from rectal
cancer [9–11]. The molecular characteristics, however, also
differ between parts of both colon and rectum [12]. These dif-
ferences may not materialise in the metastatic setting, but
may be relevant when the disease is only subclinical.
3. Evidence for effects of adjuvant
chemotherapy in rectal cancer
A Cochrane report [13], based upon 21 clinical trials including
9221 patients, concluded that significant gains are present in
both DFS and OS (Table 1). These patients have been treated
over several decades. During this extended time period, both
surgery and the use of additional (chemo)radiotherapy have
evolved considerably [6]. The hazard ratios (HRs) for gains in611 24 32;
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E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 7 2 –7 9 75rectal cancer are, according to the Cochrane report, for stages
II + III: 0.75 for DFS and 0.89 for OS. No heterogeneity was seen
between stages II and III. These HRs appear rather similar to
the ones seen in colon cancer stage II but are less than those
seen in colon cancer stage III [14–16]. Whether the relative
gains differ between colon cancer stages II and III is uncer-
tain, however, since they are to a large extent based upon in-
ter-trial comparisons. The trials predominantly including
stage III patients are generally older than those including
stage II patients. Furthermore, the estimates for stage II are
from a Cochrane report probably including all trials and pa-
tients, whereas no such report has been completed for stage
III. The large ACCENT (Adjuvant Colon Cancer Endpoints)
(Adjuvant Colon Cancer Endpoints) database gives important
information as it includes the majority of the large trials [16]
but then also tends to overestimate the gains, since all posi-
tive trials were included but not necessarily all negative trials.
Itmay thus bepossible to conclude that adjuvant treatment
for rectal cancer should be given as for colon cancer, based
upon the Cochrane analyses. Otherswould argue that the het-
erogeneity between the trials is so extensive that no firm con-
clusions can be drawn. An entirely different view was also
expressed in a recent systematic review [17] where the differ-
ent rectal cancer trials were scrutinised according to whether
the patients were pretreated, with radiotherapy only or with
chemoradiotherapy, or if they received (chemo)radiotherapy
postoperatively. These trials are summarised in Table 1.
4. Discussion of selected individual trials and
of an analysis of pooled data
4.1. QUASAR uncertain study
This trial [18] included 984 rectal cancer patients (and 2345 co-
lon cancer patients) in whom the doctors were uncertain
about the value of adjuvant chemotherapy. In the group of
rectal cancer patients, 5-year OS was increased from 74% in
the control group to 78% (HR 0.77, P = 0.05) in the group of
patients who were randomised to surgery and adjuvant
5-FU + calcium folinate. This gain was numerically the same
in those rectal cancer patients who had surgery alone
(n = 549) or preoperative (n = 198) or postoperative
(chemo)radiotherapy, albeit not statistically significant. This
is probably due to limited patient numbers in the subgroups.
This study provides the strongest individual proof that adju-
vant chemotherapy has at least some efficacy in rectal cancer.
4.2. EORTC 22921/FFCD9203 (Fe´de´ration Francophone de
la Cance´rologie Digestive)
These two trials [19–21] chiefly tested the value of concomi-
tant chemotherapy and radiotherapy in intermediate rectal
cancer, although the European Organisation for Research
and Treatment of Cancer (EORTC) trial, having a 2 · 2 design,
also explored the value of adjuvant 5-FU/leucovorin. The tri-
als (n = 1011 and 756 patients, respectively) showed that the
addition of chemotherapy decreased local recurrence rates
(HR 0.54; 0.41–0.78) but not distant progression or OS, even if
analysed together to increase power [21]. Although subgroup
analyses according to ypT stage indicated that a survival gainwas seen in the group of patients whose tumours appeared to
respond to the (chemo)radiotherapy [22], the EORTC trial ar-
gues against any relevant gain from adjuvant chemotherapy
in pretreated rectal cancer patients.
4.3. PROCTOR/SCRIPT/Chronicle (Preoperative Radiotherapy
and/oradjuvantChemotherapy combinedwithTME-Surgery in
Operable Rectal cancer/Simply Capecitabine in Rectal cancer
after Irradiation Plus TME)
Due to the scientific lack of firm evidence for benefit from
adjuvant chemotherapy in rectal cancer properly operated
and pretreated with (chemo)radiotherapy, trials with a
surgery-alone group were initiated by researchers in the
Netherlands, Sweden and the United Kingdom (UK). These trials
have unfortunately been prematurely closed for patient inclu-
sion because of poor accrual. The PROCTOR study included
patients who had preoperative 5 · 5 Gy and TME and random-
ised the patients to surgery alone or 6 months of 5-FU/leuco-
vorin. It was later changed (to SCRIPT) to capecitabine instead
of 5-FU/leucovorin. In addition, patients who had received
preoperative chemoradiotherapy could be included. In total,
over 500 patients were included in these Dutch/Swedish trials
until December 31, 2012. The UK Chronicle trial randomised
110 patients who had preoperative chemoradiotherapy to a
control group or adjuvant 5-FU/leucovorin and oxaliplatin.
There are no mature data from the trials, although an interim
report presented at a scientific meeting when 470 patients
had been included could not see any gain (van de Velde, per-
sonal communication). The trials illustrate the ambitions
from scientists to create good scientific evidence and rely on
extrapolated data as little as possible [23].
4.4. Other recent trials
In a Finish trial, 278 patients in clinical stage II + III were ran-
domised between TME alone or preoperative 5 · 5 Gy, TME
and adjuvant 5-FU/leucovorin [24]. The trial results will again
be confounded by radiotherapy, but early and late toxicity of
the combined treatment can be properly evaluated against
modern surgery alone. No increase in serious surgical compli-
cations was seen. Wound infections and perineal wound
dehiscence were, as expected, more common after irradia-
tion. If the trial turns out to be negative, it will argue against
the value of adjuvant chemotherapy since any survival gains
from 5 · 5 Gy with TME is at best limited [6]. The limited num-
ber of patients and inclusion also of patients with early stages
may prevent firm conclusions.
In two parallel identically designed German trials in colon
(n = 855) and rectal (n = 796) cancer, respectively, adjuvant 5-
FU/leucovorin was superior to 5-FU alone in colon cancer
[67% (95% CI 59–73) versus 54% (95%; CI 97–61)] – but not in
rectal cancer – [56% (95% CI 99–63) versus 51% (95% CI 43–
58)] [25]. The authors speculate that the chemosensitivity of
colon and rectal cancer differs.
4.5. Nomogram
Valentini et al. [26] collected information from a total of 2795
patients included in five European clinical trials with the aim
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adjuvant chemotherapy. The trials were heterogeneous in
many relevant aspects, and only two of them randomised
patients between adjuvant chemotherapy or not [19] (Cionini
et al, unpublished). The other three trials either planned to
give adjuvant chemotherapy to all patients [20,27] or did not
specify this in the protocol [28]. Neither of the two individual
trials exploring the value of adjuvant chemotherapy revealed
any significant gain in recurrence-free survival, whereas a
small gain was seen when all trials were pooled together.
Pooling of data from different trials may, however, easily
introduce bias. Nomograms were developed for prediction of
local recurrence, distant metastases and OS. The pathological
stage (ypTN) after preoperative treatment (most patients had
chemoradiotherapy to 45–50 Gy) was most important,
although the use of adjuvant chemotherapy gave some addi-
tional value to the models. This added value was numerically
smaller for distant metastases [HR ± 95% CI; 0.90 (0.83–0.97)]
than for local recurrence [HR ± 95% CI; 0.81 (0.72–0.92)] and
OS [HR ± 95% CI; 0.82 (0.76–0.88)]. The proposed nomogram
was considered to have reliable concordance indices (0.73
for distant metastases) and could thus be useful for clinical
assistance. The nomogram – which did not account for com-
peting risk of death for recurrence prediction, therefore
slightly overestimating the risk – indicated that any gains
from adjuvant chemotherapy were minimal (1–2%) for
responding patients, whereas the gains were larger for those
who did not respond well to the preoperative chemoradio-
therapy. The opposite conclusion was reached, as described
above, when one of the included trials [19] was analysed ret-
rospectively [22].
5. Recommendations
5.1. High rectal cancers
It is reasonable to conclude that tumours arising in the upper
peritonealised third of the rectum should be treated as if aris-
ing from the colon. This means that most stage II patients
should not have any adjuvant chemotherapy, some high-risk
stage II patients should have adjuvant fluoropyrimidine and a
few with several or very high-risk features an oxaliplatin
combination. Most stage III patients should have an oxalipla-
tin combination, although some with low-risk features, par-
ticularly if they are older than 70 years, should rather be
offered a fluoropyrimidine alone. These patients seldom have
had preoperative (chemo)radiotherapy, although this may
have been used in locally advanced, ugly tumours [6].
5.2. Non-irradiated low and medium-high rectal cancer
Adding 5FU-based adjuvant chemotherapy after surgery
alone seems to provide meaningful benefits in terms of OS
and DFS and perhaps also local recurrence rates, also in rectal
cancers from the lower two-thirds. In practice, this is not of-
ten clinically relevant since very few patients with a tumour
below about 10 cm from the anal verge with adverse histolog-
ical features have been treated with surgery alone. Clinical
and radiological imaging is not perfect, with a tendency forover-staging being more common than under-staging. What
could be discussed in these patients is whether adjuvant che-
motherapy then should be given alone or whether they
should rather have adjuvant chemotherapy with chemoradio-
therapy given either upfront or sometime during the treat-
ment period. There are no data from modern trials to rely
upon. If the local recurrence risk is reasonably high, for exam-
ple if the surgery was non-radical (R1 + R2 or crm+), chemora-
diotherapy is probably more relevant than if the risk of local
recurrence is limited but the risk of systemic relapse is higher.
Extensive lymph-node involvement (N2) and extramural
vascular invasion (EMVI+) increase the risk particularly of
systemic dissemination but also to some extent of local
recurrence. However, it appears as if trial data taken together
indicate that adjuvant chemotherapy seems more relevant
for most patients than chemoradiotherapy, although this
conclusion is controversial due to the lack of good trial data.
5.3. Pretreated rectal cancer
The ability to give solid recommendations based upon good
evidence is limited when radiotherapy and particularly che-
moradiotherapy have been given prior to surgery. Often a time
period has been present between the end of chemoradiother-
apy and surgery, and during that time period substantial
tumour regression may have been seen. Most evidence,
although based upon retrospective or pooled data, indicate
that the patients then are best treated according to the path-
ological stage. If a pCR or a good regression is seen the value
of adjuvant chemotherapy may be minimal, chiefly because
the risk of recurrence is small (<15%). The study which devel-
oped the nomogram [26] indicates that patients with poor tu-
mour regression benefit from adjuvant chemotherapy. This
author is uncertain about its value, and would have preferred
to see a randomised study completed. Still, adjuvant oxalipl-
atin-based therapy is often given, chiefly because the risk of
recurrence is high. In a United States (US) national compre-
hensive cancer network analysis [29] it was seen that a size-
able minority of the patients (about 20%) who preoperatively
received chemoradiotherapy did not receive adjuvant chemo-
therapy, as recommended. Strategies to facilitate the ability to
complete the third and final component of curative treatment
were considered necessary.
Adjuvant chemotherapy is also provided in the control
group of the ongoing RAPIDO trial (Clin Trials Gov,
NCT01558921) where locally advanced, ugly rectal cancers
are randomised between chemoradiotherapy, surgery and op-
tional adjuvant capecitabine–oxaliplatin (XELOX) for
6 months or 5 · 5 Gy, 5 months of XELOX and surgery [30].
Due to the scientific uncertainty, some countries (centres)
have chosen not to give adjuvant chemotherapy in the control
group.
6. Timing of chemotherapy
Sensitivity of the subclinical tumour cells potentially present
after surgery to the given drug(s) is for obvious reasons crucial
for an increase in recurrence-free survival, and hence DFS
and OS. However, since the currently available drugs in colo-
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number of tumour cells to be killed is also relevant. The tu-
mour cells have left the primary tumour prior to diagnosis,
between the diagnosis and the surgery (or start of a treatment
that at least temporarily prevents the tumour cells from being
clonogenic) and at the latest during the surgery to remove the
primary. The number of cells in the deposits to be killed is
also influenced by the delay from surgery to initiation of the
adjuvant therapy. The relevance of this delay has been the fo-
cus of many retrospective studies and meta-analyses of the
studies in colon cancer [31–33]. Most studies have reported
poorer survival in groups of individuals who started adjuvant
therapy later rather than earlier. The start of treatment is not
random (a randomised trial comparing different times is not
possible for ethical reasons) but may be caused by many fac-
tors that negatively influence particularly survival but also
risk of and time to recurrence. The analyses may thus be sub-
ject to severe bias. All trials that have shown a benefit from
adjuvant therapy in colon cancer had a requirement that it
should be initiated within 4–6 weeks. In later trials, the max-
imum allowed time has been much longer, up to 12–13 weeks,
actually diminishing the ability to detect a difference between
two treatments. Several national guidelines also permit a de-
lay up to 12 weeks (e.g. [34]). In a survey among 679 out of 1151
patients who received chemotherapy, only 72% met the 12-
week benchmark. This proportion was lower in rectal cancer
(67%) than in colon cancer (79%).
For many reasons, the time from diagnosis to start of adju-
vant therapy is longer in rectal cancer than in colon cancer.
The surgery is generally more extensive, with more complica-
tions and longer postoperative recovery. The preoperative
radiotherapy – which probably efficiently decreases the clono-
genic capacity of the tumour cells in the primary, but not in
the subclinical distant metastases – is another reason for a
longer delay during which tumour cell growth occurs. The
chemotherapy given concomitantly with the radiotherapy is
not very dose-efficient compared with that when it is used
alone, and probably has marginal influence on the risk of dis-
tant recurrence. The tendency to prolong the interval be-
tween the end of (chemo)radiotherapy and surgery to see
more pCRs and down-sizing [35] further prolongs the interval
and may cause survival to deteriorate. One apparently posi-
tive aspect of likely no benefit for the patients (the treatment
has already been given) may be counterbalanced by another
aspect. This also relates to the increased use of 5 · 5 Gy with
a delay of 6–8 weeks (as explored in the randomised Stock-
holm III trial [36]) outside of trials in intermediate (bad) rectal
cancers (designated by most as locally advanced) [6]. The
Stockholm III completed patient accrual in January 31, 2013,
so survival data will not be available for many years.
7. Conclusions
In many countries the use of adjuvant chemotherapy for rec-
tal cancer is not an issue, meaning that it is recommended
and given as for colon cancer. There are no good studies
describing how often it is an issue, but several centres in sev-
eral countries have expressed concerns about the value of
adjuvant chemotherapy in rectal cancer [37]. This is not the
case for colon cancer, where treatment recommendationsare probably very similar to the guidelines presented by the
European Society for Medical Oncology (ESMO) [38]. These
recommendations are based upon firm evidence when they
relate to the entire group of patients with colon cancer, but
must be questioned in the different substages. The surgery
performed today for colon cancer is of higher quality than it
was when the trials were run. Furthermore, and possibly even
more relevant, is higher quality of the pathology investiga-
tions. This has caused stage migration. The extent of this
has not been quantified. However, if we follow the recom-
mendations [38], we treat groups of patients with very low
risks of recurrence (even less than 10% with an oxaliplatin
combination), gaining very few individuals. When analysed,
population data indicate that the use in colon cancer follows
the present recommendations (e.g. [39]), whereas greater var-
iability has been reported for rectal cancer (e.g. [40]). The
available literature-based documentation from the trials has
been briefly summarised here. No one can object to the much
less scientific evidence for sufficient gains in rectal cancer
compared with colon cancer. However, interpretations differ
considerably between different researchers and clinicians,
particularly when the surgery has been preceded by
(chemo)radiotherapy.Conflict of interest statement
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